Multiple sclerosis (MS) is the most common neurological immune-mediated disease leading
to disability in young adults. The outcome of the disease is unpredictable, and over time …

The treatment of multiple sclerosis (MS) has changed over the last 20 years. All
immunotherapeutic drugs target relapsing remitting MS (RRMS) and it still remains a …

In recent years, there has been a paradigm shift in the treatment of multiple sclerosis (MS)
owing to the approval of a number of new drugs with very distinct mechanisms of action. All …

Multiple sclerosis (MS) is a chronic inflammatory autoimmune demyelinating disease of the
central nervous system. It affects approximately 400,000 people in the United States and …

In the past decade, the therapeutic arsenal for multiple sclerosis has expanded greatly.
Newer more potent disease modifying therapies (DMTs) with varying mechanisms of actions …

This review updates and extends earlier Consensus Reports related to current basic and
escalating immunomodulatory treatments in multiple sclerosis (MS). The recent literature …

Therapeutic strategies for multiple sclerosis have radically changed in the past 15 years.
Five regulatory-approved immunomodulatory agents are reasonably effective in the …

Two decades of clinical experience with immunomodulatory treatments for multiple sclerosis
point to distinct immunological pathways that drive disease relapses and progression. In …

Multiple sclerosis (MS) is the most common inflammatory disorder of the central nervous
system (CNS) in young adults. When MS is not treated, it leads to irreversible and severe …

New so-called immune reconstitution therapies (IRTs) have the potential to induce long-term
or even permanent drug-free remission in people with multiple sclerosis (MS). These …